Objective The aim of this study was to investigate the eVect of epidermal growth factor receptor (EGFR) blockade on cell survival and on downstream signalling pathways using the monoclonal antibody cetuximab. Methods We used three colon cancer cell lines, of which one was EGFR-negative, and two head and neck squamous cell carcinoma (HNSCC) lines. EGFR expression and gene copy number were measured by immunohistochemistry and FISH analysis, respectively. The eVect of cetuximab, irradiation or the combination of both on cell growth was estimated by SRB assay. Western blotting was used to determine the phosphorylation of intracellular signalling proteins and cell cycle phase distribution was measured by Xow cytometry. Results The addition of cetuximab had only limited eVects on cell growth, with a maximum inhibition of approximately 30%, but was correlated with the amount of protein expression and gene copy number of EGFR. When combined with irradiation, the eVect of cetuximab was only additive and not dependent on the inherent radio-sensitivity of the cell lines. Persistent phosphorylation of Akt and/or p44/42 MAPK was detected by western blot in all of the cell lines, whereas there was no phosphorylation of Jak2 or STAT3. Conclusions None of these factors alone could predict the sensitivity to cetuximab. Rather, the results suggest that it might be necessary to determine the activation status of several intracellular signalling proteins to better predict the sensitivity to cetuximab treatment.
Introduction
Many tumours over-express the epidermal growth factor receptor (EGFR) (Grandis and Sok 2004) . Activation of EGFR leads to increased tumour proliferation, angiogenesis, metastasis, and tumour invasiveness (Baselga 2002; Grandis and Sok 2004) . The fact that the expression of this receptor is much lower in most normal cells makes EGFR an attractive therapeutic target. Several EGFR-blocking drugs have been introduced in recent years, either small molecules that inhibit tyrosine kinases inside the cell (e.g. erlotinib, geWtinib) or antibodies that block the receptor. The most widely used anti-EGFR antibody is cetuximab, which has been shown to be particularly eVective against colorectal cancer and head and neck cancer, administered alone or in combination with chemotherapy (Cunningham et al. 2004; Herbst et al. 2005; Vermorken et al. 2007 ). In head and neck cancer, cetuximab has also been shown to increase the eVect of irradiation of some tumour sites (Bonner et al. 1994 ). This has led to the initiation of several, presently ongoing, clinical studies on cetuximab and irradiation in diVerent diagnoses. Not all patients respond to cetuximab, however.
Much eVort has been put into identifying factors that can predict treatment response, but so far these studies have shown conXicting results. Over-expression or ampliWcation of EGFR, k-ras mutations, and p53 mutations are factors that have been correlated with response to cetuximab in some, but not all, studies (Huether et al. 2005; Lievre et al. 2006; Moroni et al. 2005) . EGFR is involved in several diVerent cellular functions. Three major signalling pathways downstream of EGFR have been identiWed: the Ras/Raf/ p44/42 mitogen-activated protein kinase (MAPK) pathway, the PI3K/Akt pathway, and the Jak/STAT3 pathway (Jorissen et al. 2003) . Ras/MAPK upregulates cyclin D1, leading to increased G1 cell cycle progression (Lavoie et al. 1996) . Activation of PI3K/Akt also aVects G1 cell cycle progression, mediated by phosphorylation of p27, and it promotes cell survival by phosphorylation of BAD (Datta et al. 1997; Shin et al. 2002) . Jak2/STAT3 signalling aVects several cellular functions such as cell cycle progression and cell survival (Siavash et al. 2004 ). Induction of these pathways is mediated by phosphorylation of the proteins involved. Thus, it is reasonable to assume that the phosphorylation status of MAPK, Akt, Jak2, and STAT3 would be of interest regarding the eYcacy of anti-EGFR treatment.
In the present study, Wve diVerent cancer cell lines derived from the colon or the head and neck were characterised with regard to EGFR status, cell cycle phase alterations, and phosphorylation of key downstream molecules. These data were in turn correlated to the sensitivity of the cell lines to cetuximab, either administered alone or in combination with irradiation.
Materials and methods

Chemicals
Cetuximab was obtained from ImClone Systems, Inc. (New York, NY, USA).
Cell lines and growth conditions
The tumour cell line LU-HNSCC-4 was originally established from a highly diVerentiated squamous cell carcinoma of the Xoor of the mouth (T2 N0 M0) and LU-HNSCC-7 was established from a recurrence of a moderately diVerentiated squamous cell carcinoma of the bucca (rT2 N0 M0). Both of these cell lines have previously been shown to be aneuploid by Xow cytometry. AmpliWcation of cyclin D1 gene encoding was found in LU-HNSCC-4 but not in LU-HNSCC-7. LU-HNSCC-4 was found to have a mutation in p53 (exon 7, AGG ! GGG) whereas LU-HNSCC-7 was found to have a wild-type p53 (no mutations in exons 5-11) (Henriksson et al. 2006) . The colon cancer cell lines RKO and WiDr were obtained from LGC Promochem (Teddington, UK) and the S1 cell line was derived from the S1 clone of LS-180 colon carcinoma cells (Miyake et al. 1999) .
All cell lines were maintained at 37°C in Dulbecco's modiWed Eagle's medium (DMEM) supplemented with 10% heat-inactivated foetal calf serum (FCS) and antibiotics (100 units/ml penicillin and 100 units/ml streptomycin sulphate) with a humidiWed atmosphere of 5% CO 2 . Tests for mycoplasma infection were negative.
Immunohistochemistry
The cells were trypsinised and Wxed in 4% buVered formalin solution, and paraYn-embedded as cell blocks using the Shandon Cytoblock Kit (Thermo Electron Corp., Pittsburgh, PA, USA). Cell blocks were cut in 4-m sections and stained using the TechMate 500 autostainer (Ventana Biotek, Tucson, AZ, USA). The primary antibody was anti-EGFR clone E30 (DakoCytomation, Glostrup, Denmark), and the ChemMate EnVision Detection Kit (also DakoCytomation) was used for detection of this antibody.
Fluorescence in situ hybridization (FISH) analysis FISH analysis of EGFR gene ampliWcation was performed using the standard method with the EGFR/CEN-7 FISH Probe Mix (DakoCytomation). BrieXy, 2.0 £ 10 5 cells in 200 l phosphate buVered saline (PBS) were placed on slides and air-dried. The cells were dehydrated in ethanol and air-dried, and then 10 l of probe was dropped onto the slides and the cells denatured for 5 min at 82°C. The slides were incubated with probe overnight at 45°C and then washed with saline-sodium citrate buVer at 65°C. The cells were dehydrated again in ethanol and air-dried. Nuclei were counterstained with VECTASHIELD Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA, USA).
Hybridisation signals were analysed using a Zeiss Axioplan 2 epiXuorescence microscope equipped with a dual band-pass Xuorescence Wlter (Chromatechnology, Brattleboro, NV, USA), which enables simultaneous detection of both green (500-600 nm) and red (600-700 nm) Xuorescence. Hybridisation signals from 70 nuclei were counted in each sample and assessed for ampliWcation or aneuploidy: cells with an EGFR/chromosome 7 ratio of ¸1.5 were considered ampliWed for EGFR, while cells in which both EGFR and the chromosome 7 centromere were equally elevated were regarded as aneuploid.
Growth inhibition assay
To measure the eVect on cell growth, 500 viable cells (in 100 l growth medium) were seeded per well in 96-well plates. After 48 h, new medium with 50 nM (7.6 g/ml) cetuximab was added and the cells incubated for 4-6 days (Wve doubling times). The growth inhibitory eVects were evaluated using the sulphorhodamine B (SRB) assay as described below. All experiments were done at least in triplicate.
Irradiation
For the irradiation experiments, 300-500 viable cells were seeded in 100 l growth medium in 96-well plates. After 48 h, new medium with 50 nM (7.6 g/ml) cetuximab was added and the cells incubated for 24 h. In order to give a homogenous dose to every well, all spaces between the wells were Wlled with sterilised water before the plates were irradiated. Irradiation of the cells was performed with 6 mV photons from a medical linear accelerator (Elekta Sli; Elekta, Stockholm, Sweden). The dose rate was 3 Gy/min. Five days after irradiation, the growth inhibition was evaluated using SRB assay as described below. All experiments were done in triplicate.
Sulphorhodamine B (SRB) assay SRB assay, based on the measurement of cellular protein content (Skehan et al. 1990) , was used to evaluate the growth inhibitory eVects of cetuximab and/or irradiation. We used the procedure described by the manufacturer of the In Vitro Toxicology Assay Kit, Sulphorhodamine B-based (Sigma-Aldrich, Saint Louis, MO, USA) with some modiWcations according to the SRB protocol from Biomol (Biomol International, Plymouth Meeting, PA, USA).
The cells were Wxed by adding 50 l ice-cold 50% (w/v) trichloroacetic acid (TCA) to each well and left for 1 h at 4°C. The supernatant was discarded, and the plates were rinsed with tap water Wve times and air-dried. The Wxed cells were stained in 50 l SRB solution (0.4% w/v SRB in 1% acetic acid) for 20 min at room temperature. After staining, the plates were rinsed Wve times with 1% acetic acid to remove unbound SRB, and again allowed to air-dry. The dye was dissolved in 150 l 10 mM Tris base and the absorbance at 570 nm was measure in a Multiscan MS spectrophotometer (Labsystems, Helsinki, Finland).
Cell cycle phase distribution
Three millilitres of growth medium containing 6.0 £ 10 5 viable cells was added to 60-mm dishes. After 48 h 50 nM (7.6 g/ml) cetuximab was added, and after another 48 h the cells were harvested by trypsinization, resuspended in citrate buVer (pH 7.6) containing 5% DMSO, and stored at ¡20°C. After thawing, cells were stained with saponin/propidium iodide/RNase solution (50 g/ml propidium iodide, Sigma-Aldrich, Saint Louis, MO, USA), 0.6% Nonidet P-40, and 0.1 mg/ml RNase (Sigma-Aldrich, Saint Louis, MO, USA) in PBS and analysed by Xuorescence-activated cell sorting (FACS) using FACSCalibur and ModFitLT V3.1 (BD Biosciences, San Jose, CA, USA) (Mullen 2004 ).
Western blot analysis
For western blot analysis, 8 £ 10 5 viable cells in 10 ml of growth medium were seeded in 100-mm dishes. After 72 h, the cells were treated for 4 h with 100 nM (15.2 g/ml) cetuximab; in some cases, this was followed by 15 min of incubation with 10 ng/ml epidermal growth factor (EGF) (Invitrogen, Carlsbad, CA, USA) in fresh medium. Cells were lysed directly on the plates by adding 500 l ice-cold RIPA buVer (1% Triton X-100, 0.1% sodium deoxycholate, 150 mM NaCl, 1 mM 4-(2-aminoethyl)benzenesulphonyl Xuoride hydrochloride [AEBSF], 2 mM Na 3 VO 4 , 1 mM NaF, 20 mM Na 4 P 2 O 7 , and 1 mM EDTA in 50 mM Tris-HCl buVer, pH 7.4). The protein concentration of the lysates was determined using the Micro BCA Protein Assay Kit (Pierce, Rockford, IL, USA) and 15 g of protein per sample was separated on 4-12% NuPAGE Bis-Tris gels with 3-(N-morpholino)propanesulphonic acid (MOPS) buVer and transferred to polyvinylidene diXuoride (PVDF) membrane (Invitrogen, Carlsbad, CA, USA). Immunoreactivity was probed with antiphospho-p44/42 MAPK (Thr202/Tyr204), anti-phospho-Akt (Ser473), and anti-phospho-Stat3 (Tyr705) antibodies from Cell Signaling Technology (Danvers, MA, USA), and antiphospho-JAK2 (Tyr1007/1008) antibody from Upstate (Lake Placid, NY, USA). Anti-pan-actin antibody from Cell Signaling Technology was used as loading control. The primary antibody was detected with a horseradish peroxidaseconjugated anti-rabbit IgG and ECL-plus detection reagent (Amersham Biosciences, Little Chalfont, UK).
For the Jak2 analysis, we used the human erythroleukemia cell line UT7 as a positive control, since stimulation of this cell line with erythropoietin has been shown to result in Jak2 phosphorylation (Ammarguellat et al. 2001) . The human epidermoid carcinoma cell line A431 was exposed to EGF and served as a positive control for STAT3 phosphorylation as previously described (Olayioye et al. 1999 ).
Statistics
Mann-Whitney test was used to compare the proportions of cells in G 0 /G 1 and S phase of the cell cycle.
Results
EGFR expression
We performed immunohistochemical analysis to determine the cell surface expression of EGFR in all Wve cell lines (Fig. 1) . Staining was scored as follows: 0, no membranous staining in any of the cells; 1+, weak-intensity membranous and cytoplasmic staining of nearly equal intensity; 2+, moderate to strong staining mainly in the membranes; and 3+, strong staining clearly localised to the cell membranes. The highest intensity of staining (3+) was seen in LU-HNSCC-4 and LU-HNSCC-7 cells, and there was weaker staining in S1 and WiDr cells (1+). No EGFR staining was detected in the RKO cell line.
EGFR gene amplication
The EGFR gene ampliWcation status was analyzed by FISH analysis (Table 1) . RKO and S1 cells showed normal signals for EGFR and chromosome 7 per tumour cell. WiDr and LU-HNSCC-7 cells were aneuploid with equally increased EGFR and chromosome 7 signals, i.e. increased gene copy number but no ampliWcation. LU-HNSCC-4 was the only cell line that showed ampliWcation of EGFR.
Growth-inhibitory eVects of cetuximab
In the EGFR-negative RKO cells, cetuximab had no inhibitory eVect at all (Fig. 2) . In the four EGFR-positive cell lines cetuximab induced growth inhibition, with some dose dependency. Doses of cetuximab above 50 nM (7.6 g/ml) did not add to the eYcacy of inhibition; this dose was therefore used in the subsequent experiments.
EVect of cetuximab in combination with irradiation
The eVect of irradiation alone is presented in terms of survival fraction at 2 Gy (SF 2 ) ( Table 2 ). S1 proved to be the most radio-sensitive of the Wve cell lines whereas WiDr was clearly more radio-resistant than the others.
The eVect of cetuximab treatment on radiation sensitivity was measured in the 0-2 Gy dose range. At higher doses of radiation, colorimetric methods for quantitation of cell survival (e.g. MTT, SRB) have been shown to give falsepositive measures of cell survival compared to colony forming assay (GriVon et al. 1995; Henriksson et al. 2006 ). Colony-forming assays, on the other hand, could not be used as not all of the cell lines formed colonies. Thus, using SRB, which has been reported to yield similar results to those of colony-forming assays at clinically relevant doses (1-3 Gy) (Pauwels et al. 2003) , the addition of cetuximab to irradiation resulted in reduced cell survival in the EGFRpositive cell lines, along the radiation dose range of 0-2 Gy (Fig. 3) . Due to the lack of a dose-eVect relationship for cetuximab in the cell lines, no mathematical test for synergy could be performed.
The eVect of cetuximab on the cell cycle
In general, cetuximab caused only minor changes in the cell cycle phase distribution (Fig. 4) . In LU-HNSCC-7 and LU-HNSCC-4 cells, exposure to cetuximab caused a slight increase in the number of cells in G 0 /G 1 with a comparable decrease in S phase, of which only the eVect on the LU-HNSCC-7 cell line was statistically signiWcant.
EVect of cetuximab on EGFR signalling
Cell line-speciWc patterns in the phosphorylation status of the four proteins were found (Fig. 5) . EGF-induced phosphorylation of MAPK protein was inhibited by cetuximab treatment in all cell lines except RKO, but only to a limited degree in WiDr cells. Akt was phosphorylated at baseline in all cell lines except WiDr and was not aVected by cetuximab. There was no phosphorylation of Jak2 or STAT3 in any of the cell lines, either at baseline or after exposure to EGF or cetuximab.
Discussion
In this study, Wve cell lines of diVerent origin were characterised with regard to their sensitivity to cetuximab, their status regarding EGFR gene copy number and ampliWcation, and downstream signalling activity of EGFR. One of the cell lines (RKO) was completely resistant to cetuximab. The eVect of cetuximab in the two other colon cancer cell lines was quite limited, with less than 20% growth inhibition, whereas the two HNSCC cell lines were slightly more sensitive (approximately 30% inhibition). This indicates Fig. 3 Growth inhibition caused by irradiation at 0, 0.5, 1 and 2 Gy alone or in combination with 50 nM (7.6 g/ml) cetuximab. Error bars indicate SEM Fig. 4 Cell cycle phase distribution in the Wve cell lines at baseline and after 48 h exposure to cetuximab. Columns represent the median values from six samples. *P < 0.05 (Mann-Whitney) for the increase in G 0 /G 1 and decrease in S phase that cetuximab had lower eYcacy than has been described in previous studies, with growth inhibition of 60-70% in the most cetuximab-sensitive cell lines (Janmaat et al. 2003; Raben et al. 2005) . In line with this, the eVects on cell cycle distribution were also smaller than expected. In fact, only one of the slightly more sensitive cell lines, LU-HNSCC-7, showed a statistically signiWcant increase in the proportion of cells in G 0 /G 1 after 48 h incubation. Similar low eVects on cell cycle distribution of relatively cetuximab resistant cell lines have previously been reported even if not as consistently, in several cell lines, as in the present work (Kiyota et al. 2002; Raben et al. 2005) . We found a correlation between the eVect of cetuximab and EGFR status, both in terms of protein expression detected by immunohistochemistry and gene copy number/ ampliWcation. The former partly contrasts with several clinical observations that have failed to Wnd a correlation between tumour response and immunohistochemical staining of EGFR (Chung et al. 2005) , whereas gene copy number and ampliWcation of the EGFR gene have shown to be predictive of the response to cetuximab in several recent clinical studies (Lievre et al. 2006; Moroni et al. 2005) .
The combination of cetuximab and irradiation led to a slightly increased cell growth inhibition in the cetuximabsensitive cell lines compared to radiation alone. The survival curves were basically parallel (Fig. 3) , suggesting that the eVect was additive and not synergistic. Cetuximab and other EGFR inhibitors have previously been shown to increase sensitivity to radiation in diVerent cell lines, including HNSCC and colorectal cancer cell lines (Bianco et al. 2002; Huang et al. 1999; Raben et al. 2005) , whereas the results of our study do not support any synergy between cetuximab and radiation. The reason for these variations might be diVerences in the inherent properties of the cell lines used. In analogy, varying responses in radio-sensitivity have been reported for diVerent cell lines treated with (Bonner et al. 1994; Sutherland 1989, 1991; Wollman et al. 1994 ). Raben et al. found a relationship between synergy and cetuximab sensitivity in nonsmall cell lung cancer cell lines, with the most sensitive cell lines showing the highest synergy and the least sensitive one showing no synergy (Raben et al. 2005) . Possibly, factors inXuencing cetuximab sensitivity also aVect the synergy between cetuximab and radiation. Our experiments showed that the additional eVect achieved by combining cetuximab with irradiation was similar in both the radiosensitive S1 line and in the radio-resistant WiDr line (Fig. 3) . Thus, the pattern of radio-sensitisation by cetuximab appears to have been independent of the inherent level of radio-sensitivity.
Stimulation of the EGF receptor may lead to activation of several diVerent pathways downstream of the receptor. In some tumours, these pathways are constitutively activated, independently of whether EGFR is activated or blocked by medications. One example is that tumours with k-ras mutations rarely respond to anti-EGFR treatment (Lievre et al. 2006) . Persistent activation of downstream proteins is another mechanism that may confer resistance. Recent studies appear to corroborate this hypothesis. For example, persistent activation of either the MAPK pathway or the PI3K/Akt pathway has previously been associated with lack of sensitivity to EGFR inhibitors (Janmaat et al. 2003) . In the present study, activation of both pathways was observed in a cell line-speciWc manner (Fig. 5) . In all but one of the cell lines, Akt was constitutively phosphorylated and unaVected by either EGF stimulation or cetuximab treatment. MAPK was phosphorylated and unaVected by EGFR manipulation in the EGFR-negative RKO cells. In the four EGFR-positive cell lines, MAPK responded to EGF stimulation and cetuximab treatment reduced the phosphorylation in all but the WiDr cells.
Thus, we found persistent activation of either MAPK or Akt, or both, in all the cell lines-also in the EGFR-positive and partly cetuximab-sensitive cell lines. This may also explain the relatively limited eYcacy of cetuximab in these cell lines, and it may explain the very modest eVect on cell cycle progression after cetuximab exposure (Fig. 4) .
Constitutive activation of STAT3 independently of EGFR status has been reported to be present in various malignant tumours, especially in HNSCC (Bromberg 2002; Sriuranpong et al. 2003) . In another study, STAT3 activation was suggested as a predictive marker of chemotherapy resistance (Barre et al. 2007) . One of the possible mechanisms for increased STAT3 activity is excessive upstream phosphorylation of Jak2 (Bromberg 2002) . In the present study both of these proteins were analyzed, but phosphorylation of STAT3 or Jak2 was not observed in any of the cell lines, either at baseline or after exposure to EGF. The lack of STAT3 phosphorylation is surprising in light of the described importance of STAT3 in EGFR signalling (Song and Grandis 2000) and STAT3 activity aberrations in cancer development (Bowman et al. 2000) . STAT3 regulates the transcription of several factors involved in cell cycle progression and apoptosis and the lack of STAT3 phosphorylation, indicating that EGFR signals through other intracellular pathways in these cell lines, might contribute to the minor eVects of cetuximab on cell cycle distribution.
The Wndings discussed above show the complexity of the EGFR cascade. In the future, it may be necessary to include analysis of phosphorylation status in multiple downstream proteins to identify the patients that are most likely to beneWt from anti-EGFR treatment. On the other hand, the speciWc inhibitors of the MAPK and Akt pathways that are now being developed will hopefully improve the antitumour eVect when combined with EGFR-blocking agents.
